Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) reported third-quarter 2025 financial results and highlighted steady progress across its two clinical-stage DNA damage response (DDR) programs, citing emerging signs of …
Aprea Advances Dual DDR Programs as Early Signals of Drug Activity Strengthen Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported third-quarter 2025 financial results and detailed a series of clinical, operational, and intellectual-property developments that the company says position its lead …
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise Read More
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) reported third-quarter 2025 financial results and outlined key progress across its oncology pipeline, including two drug candidates now moving toward clinical development …
Prelude Advances Two Novel Cancer Programs as Cash Runway Extends Into 2027 Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported third-quarter results and detailed an intensifying slate of clinical milestones as its QTORIN platform advances across four rare dermatologic diseases — …
Palvella Races Toward Key 2026 Readouts as Rare-Disease Pipeline Expands Rapidly Read More
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) reported third-quarter financial results and outlined steady progress across its upliFT-D gene therapy program, positioning the company for critical regulatory and clinical …
Passage Bio Pushes Toward Key 2026 Milestones as Gene Therapy Program Accelerates Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) reported third-quarter financial results and said it is preparing to submit a New Drug Application (NDA) for its lead candidate, lorundrostat, by …
Mineralys Nears Pivotal FDA Filing as Hypertension Drug Lorundrostat Advances Read More
PHILADELPHIA, PA — Vittoria Biotherapeutics, Inc. announced it will present interim clinical data from its first-in-human Phase 1 study of VIPER-101, a CD5-modulated autologous CAR-T therapy, at the upcoming American …
New CAR-T Data Could Upend T-Cell Lymphoma Care — Vittoria Prepares First Reveal Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled compelling new data from its Phase 2 study of VP-315, a first-in-class oncolytic peptide immunotherapy, showing strong local immune activation …
New Cancer Data Hints at a Surgery-Free Future — Verrica’s VP-315 Shows Big Promise Read More
WILMINGTON, DE — AstraZeneca reported statistically significant Phase III results showing that Fasenra (benralizumab) can substantially delay disease worsening for patients with hypereosinophilic syndrome (HES), a rare and potentially life-threatening …
AstraZeneca’s Fasenra Shows Major Breakthrough in Delaying HES Disease Flares Read More
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) unveiled new two-year data showing that its flagship therapy Rezdiffra produced sustained improvements in patients with compensated MASH cirrhosis, a population with …
Breakthrough Liver Drug Shows Powerful Two-Year Gains — But Raises a Critical Warning Read More